Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. May 27, 2024; 16(5): 1320-1327
Published online May 27, 2024. doi: 10.4240/wjgs.v16.i5.1320
Comparative observation of the effectiveness and safety of remimazolam besylate versus dexmedetomidine in gastrointestinal surgery in obese patients
Yu-Fu Deng, Xue-Run Jiang, Zeng-Guang Feng
Yu-Fu Deng, Xue-Run Jiang, Zeng-Guang Feng, Department of Anesthesiology, Xiangtan Central Hospital, Xiangtan 411100, Hunan Province, China
Author contributions: Deng YF designed the research and wrote the first manuscript; Deng YF, Jiang XR and Feng ZG contributed to conceiving the research and analyzing data; Deng YF conducted the analysis and provided guidance for the research; all authors reviewed and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Xiangtan Central Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: All data and materials are available from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zeng-Guang Feng, BMed, Director, Department of Anesthesiology, Xiangtan Central Hospital, No. 120 Heping Road, Xiangtan 411100, Hunan Province, China. FZG17320275@163.com
Received: February 19, 2024
Revised: April 2, 2024
Accepted: April 9, 2024
Published online: May 27, 2024
Processing time: 94 Days and 2.3 Hours
Core Tip

Core Tip: This study primarily compared the effectiveness and safety of remimazolam besylate versus dexmedetomidine (DEX) in gastrointestinal surgery for obese patients. Our findings confirmed that remimazolam besylate was significantly more effective than DEX in gastrointestinal surgery in obese patients, with a high safety profile and value in clinical promotion, thereby providing a reliable clinical reference for anesthesia management optimization in gastrointestinal surgery for obese patients.